Nestle set to sell $5 pizza, sandwiches for Wegovy, Ozempic users
New brand boosts protein, iron, calcium content
Up against new Daily Harvest, Herbalife products
By Jessica DiNapoli
NEW YORK, May 21(Reuters) -Nestle NESN.S will market a new, $5 line of frozen pizzas and protein-enriched pastas in the United States which it says it designed specifically for people taking drugs such as Wegovy or Ozempic for weight loss.
The world's biggest food company, which sells DiGiorno pizza and Stouffer's meals to major grocers, said it developed the new products with more protein, iron and calcium for people taking the wildly popular appetite-suppressing drugs, called GLP-1 agonists.
Tom Moe, president of Nestle USA's meal division, said it will pitch the meals in a new brand, Vital Pursuit, as "food solutions" for people who want to complement their use of the drugs with "the right nutrition - high protein, good fiber, the right minerals," like potassium and vitamin C.
The products, set to hit supermarket shelves in October, are priced at $4.99 and under, a little more expensive than a DiGiorno four cheese personal pan pizza, which is sold at Target for $4.79.
Nestle, whose biggest brands include KitKat chocolate bars and Nescafe coffee, started working on companion products to the GLP-1 drugs last year.
"We moved real fast on this," Moe said.
Nestle CEO Mark Schneider said in October the company was “carefully” monitoring whether spreading use of the drugs might dent demand for its food products. He also said at the time that Nestle was working on “companion products” that might serve to limit the "loss of lean muscle mass” in people on the drugs.
Some investors have been worried that food companies will lose sales due to the hunger-suppressing drugs. But executives at companies like Nestle and Conagra CAG.N see the medications presenting a new opportunity to pitch products such as beef jerky, popcorn and frozen meals. Mondelez MDLZ.O executives have said their snack bars fit perfectly into the diet of a GLP-1 patient.
Roughly one in eight U.S. adults have taken the GLP-1 drugs, but Goldman Sachs estimates that 10 million to 70 million U.S. consumers could be taking them in the next four years.
Moe said Nestle spoke with people on the drugs to develop the meals and will be offering them samples soon. The Swiss-based company first introduced the brand to Walmart WMT.N, and then other big retailers such as Kroger KR.N and Target TGT.N, he said.
RACE ON TO FILL PROTEIN GAP
People on GLP-1 medications are at risk of losing lean muscle mass as they shed pounds and often don’t feel like eating very much, said Ethan Lazarus, an obesity doctor in Colorado. Some who take the drugs develop aversions to protein and fat, said Lazarus, who is a speaker for GLP-1-drugmakers Eli Lilly LLY.N and Novo Nordisk NOVOb.CO.
“There’s definitely a need to make sure people get adequate protein,” said Lazarus, who once served on the advisory board for Nestle Health Sciences, which makes Optifast, a weight loss product.
“If food companies are going to try to pivot to make simple-flavored foods that are rich in protein and easy on the stomach, they might be popular ... I’m not sure how it’s different from (previous generations of packaged) diet food.”
Nestle already makes weight loss shakes and supplements that cater to people on the drugs, who can experience side effects like nausea and constipation.
Nutrition company Herbalife HLF.N earlier this year began selling some of its most popular shake mixes and fiber supplements in bundles targeting people on the drugs.
Herbalife is looking at expanding the bundles to other markets, including South America and in particular Brazil, where GLP-1 drugs are growing in popularity, said Luigi Gratton, chairman of the company's nutrition advisory board.
Meal kit provider Daily Harvest is also offering a GLP-1 companion food collection, a box of meals that includes a broccoli and white bean soup and bean and cabbage bowl for $118.46.
Sales have been "relatively slow," said Daily Harvest CEO Ricky Silver. The company isn't aggressively pushing into selling its kits to people on the medications, he said.
"We definitely see it as an opportunity (but) not something we need to drastically pivot our focus toward," Silver said. "Our food is already foundationally good for people taking these drugs."
Nestle's Vital Pursuit's portions will range from approximately eight to 10 ounces (227 to 284 grams), Moe said.
In the 1980s, Nestle introduced diet brand Lean Cuisine, with meals focused on calorie control, while Vital Pursuit offers more fiber, protein and other "macronutrients," Moe said.
Reporting by Jessica DiNapoli in New York; Editing by Sonali Paul
Relaterade tillgångar
Senaste nytt
Ansvarsfriskrivning: XM Group-enheter tillhandahåller sin tjänst enbart för exekvering och tillgången till vår onlinehandelsplattform, som innebär att en person kan se och/eller använda tillgängligt innehåll på eller via webbplatsen, påverkar eller utökar inte detta, vilket inte heller varit avsikten. Denna tillgång och användning omfattas alltid av i) villkor, ii) riskvarningar och iii) fullständig ansvarsfriskrivning. Detta innehåll tillhandahålls därför uteslutande som allmän information. Var framför allt medveten om att innehållet på vår onlinehandelsplattform varken utgör en uppmaning eller ett erbjudande om att ingå några transaktioner på de finansiella marknaderna. Handel på alla finansiella marknader involverar en betydande risk för ditt kapital.
Allt material som publiceras på denna sida är enbart avsett för utbildnings- eller informationssyften och innehåller inte – och ska inte heller anses innehålla – rådgivning och rekommendationer om finansiella frågor, investeringsskatt eller handel, dokumentation av våra handelskurser eller ett erbjudande om, eller en uppmaning till, en transaktion i finansiella instrument eller oönskade finansiella erbjudanden som är riktade till dig.
Tredjepartsinnehåll, liksom innehåll framtaget av XM såsom synpunkter, nyheter, forskningsrön, analyser, kurser, andra uppgifter eller länkar till tredjepartssajter som återfinns på denna webbplats, tillhandahålls i befintligt skick, som allmän marknadskommentar, och utgör ingen investeringsrådgivning. I den mån som något innehåll tolkas som investeringsforskning måste det noteras och accepteras att innehållet varken har varit avsett som oberoende investeringsforskning eller har utarbetats i enlighet med de rättsliga kraven för att främja ett sådant syfte, och därför är att betrakta som marknadskommunikation enligt tillämpliga lagar och föreskrifter. Se till så att du har läst och förstått vårt meddelande om icke-oberoende investeringsforskning och riskvarning om ovannämnda information, som finns här.
